Drug Type Radionuclide Drug Conjugates (RDC), Therapeutic radiopharmaceuticals |
Synonyms- |
Target |
Action antagonists |
Mechanism SSTR2 antagonists(Somatostatin receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neuroendocrine Tumors | Preclinical | China | 16 Oct 2024 | |
Small Cell Lung Cancer | Preclinical | China | 16 Oct 2024 |